Drug profile · INN
dabrafenib
TAFINLAR
dabrafenib (TAFINLAR) is a serine/threonine-protein kinase b-raf inhibitor. Associated with Novartis Pharmaceuticals.
EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01EC02
Patents linked 0
Pipeline programs 7
News articles 1
Drug details — dabrafenib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 7
- Data quality
- 0.83
Quick answer
dabrafenib (TAFINLAR) is a serine/threonine-protein kinase b-raf inhibitor. Associated with Novartis Pharmaceuticals.
Key facts
INN dabrafenib
Brand TAFINLAR
Mechanism Serine/threonine-protein kinase B-raf inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EC02
Originator Novartis Pharmaceuticals
Mechanism of action
Serine/threonine-protein kinase B-raf inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dabrafenib?
dabrafenib (TAFINLAR) is a serine/threonine-protein kinase b-raf inhibitor. Associated with Novartis Pharmaceuticals.
What is the brand name for dabrafenib?
TAFINLAR is a marketed brand name for dabrafenib. Check FDA Drugs@FDA for the current US label holder and prescribing information.